Annis Gardner Whiting Capital Advisors LLC Acquires 50,681 Shares of Novo Nordisk A/S $NVO

Annis Gardner Whiting Capital Advisors LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 677.6% during the 1st quarter, Holdings Channel reports. The institutional investor owned 58,161 shares of the company’s stock after acquiring an additional 50,681 shares during the quarter. Annis Gardner Whiting Capital Advisors LLC’s holdings in Novo Nordisk A/S were worth $2,138,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Revolve Wealth Partners LLC grew its position in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after buying an additional 200 shares during the last quarter. AQR Capital Management LLC boosted its holdings in Novo Nordisk A/S by 21.0% in the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after acquiring an additional 10,758 shares during the last quarter. Sivia Capital Partners LLC increased its position in Novo Nordisk A/S by 18.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock valued at $712,000 after purchasing an additional 1,587 shares during the period. Invesco Ltd. raised its holdings in Novo Nordisk A/S by 26.3% during the 2nd quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock worth $28,967,000 after purchasing an additional 87,467 shares during the last quarter. Finally, Gamco Investors INC. ET AL bought a new position in Novo Nordisk A/S during the 2nd quarter worth approximately $314,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Down 2.3%

NVO stock opened at $50.29 on Friday. The stock’s 50 day simple moving average is $46.09 and its 200 day simple moving average is $45.83. The company has a market cap of $224.56 billion, a P/E ratio of 11.81, a price-to-earnings-growth ratio of 4.70 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $71.79.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The firm had revenue of $10.85 billion during the quarter. On average, research analysts expect that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: India approved Wegovy for treating MASH, expanding the drug’s potential beyond obesity into fatty liver disease and opening another large growth opportunity. Reuters article
• Positive Sentiment: Novo launched oral Wegovy in Europe after winning European Commission approval, giving it the first GLP-1 pill for weight management in the region and strengthening its first-mover advantage. Yahoo Finance article
• Positive Sentiment: Reuters reported Novo will launch a lower-cost authorized copy of Ozempic in South Africa, a move that could expand access and support volume growth in an important emerging market. Reuters article
• Neutral Sentiment: Analysts at Erste Group trimmed FY2026 EPS estimates slightly to $3.22 from $3.23, a minor cut that does not materially change the current outlook but signals some caution. MarketBeat article
• Neutral Sentiment: Brokerages continue to rate Novo Nordisk around “Hold,” suggesting the recent rally is being met with a more balanced valuation view. American Banking News article
• Negative Sentiment: Some commentary notes that Eli Lilly still has a chance to win parts of the GLP-1 market, highlighting competitive risk even as Novo’s pill gains traction. The Motley Fool article

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on NVO shares. Weiss Ratings downgraded shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, April 22nd. Wolfe Research assumed coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They set a “peer perform” rating for the company. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, Zacks Research downgraded Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Five analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.